Miriam M. Yeung

Parkville, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC.

Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC.

Journal: Clinical and translational radiation oncology
Published: August 22, 2023

Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study.

Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study.

Journal: Cancer discovery
Published: December 30, 2021

Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses.

Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses.

Journal: Cancer cell
Published: December 13, 2021

HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults.

HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults.

Journal: Nature medicine
Published: November 11, 2020

Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.

Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.

Journal: PLoS medicine
Published: October 25, 2019

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.

Journal: Science (New York, N.Y.)
Published: October 23, 2019

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia.

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia.

Journal: Nature communications
Published: March 13, 2019

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.

Journal: Cancer discovery
Published: September 29, 2018

HBO1 is required for the maintenance of leukaemia stem cells.

HBO1 is required for the maintenance of leukaemia stem cells.

Journal: Nature
Published: September 05, 2018
Showing 1-9 of 9

Last Updated: 09/26/2026